Liège, Belgium, 17 November 2022 – 17:50 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that following of the Company’s first and second drawdowns under the loan facility entered into with funds managed by Highbridge Capital Management, LLC (“Highbridge”) and funds managed by Whitebox Advisors, LLC (“Whitebox”, and jointly with Highbridge , each a “Lender”), a new part of the loans was provided in kind by Highbridge against the issue of new shares.